A third dose of the Pfizer vaccine is currently authorized for Americans who received their second dose at least six months ago and are ages 65 and older, have a job that increases their risk of infection or are at high risk of severe COVID-19.
Seven updates on COVID-19 booster shots in the U.S.:
- Preliminary research shows that fully vaccinated people who have had a breakthrough COVID-19 infection have strong protection and don’t need to rush to get a booster dose. A number of preliminary studies have indicated a bout with COVID-19 after full vaccination essentially acts as an extra dose, prompting the immune system to generate B cells and T cells.
- As of Oct. 6, more people on average were getting a booster shot each day than the number of people receiving a first dose of the vaccine.
- Prominent physicians and scientists have asked the White House to scale back its booster plan, saying current data on COVID-19 vaccines’ efficacy doesn’t justify the broad use of boosters and the shots should only be offered to Americans at high risk of severe COVID-19.
- Johnson & Johnson filed for emergency use authorization from the FDA Oct. 5 for a booster dose of its vaccine for people ages 18 and older. The drugmaker said its submission to the FDA to support authorization of a booster includes data from a phase 3 trial that found a booster dose given 56 days after the first dose was 94 percent effective at preventing symptomatic COVID-19. The trial also showed the booster was 100 percent effective against severe or critical COVID-19 at least 14 days after vaccination.
- The FDA said Oct. 1 that its Vaccines and Related Biological Products Advisory Committee will meet Oct. 14 to discuss granting emergency use authorization to Modena for a third dose of its vaccine in people ages 18 and older. On Oct. 15, the committee will meet to discuss authorizing a booster of Johnson & Johnson’s vaccine for people 18 and older. The same day, the committee plans to discuss allowing people to receive booster doses produced by a different drugmaker than the manufacturer of the original vaccine they received.
- Many pharmacies are administering COVID-19 booster shots to people without requiring proof of eligibility for the shot under CDC standards.
- A CDC report released Sept. 28 found that side effects of a third dose of either Pfizer or Moderna’s COVID-19 vaccine are similar to those experienced after a second dose.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
